Purinostat Mesylate

Small molecule

Phase 3underway

Evidence outlook · registrational

Diffuse Large B-Cell Lymphoma: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2029-06-30.

Also in development:Multiple Myeloma · Phase 1/2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Diffuse Large B-Cell Lymphoma
Phase 2 (2)
Diffuse Large B-Cell Lymphoma
NCT05563844 · Chengdu Zenitar Biomedical Technology Co., Ltd
2022-11-08 – 2027-12-01 · Diffuse Large B Cell Lymphoma,DLBCL
What this study did
Other / comorbidity
NCT06485219 · Chengdu Zenitar Biomedical Technology Co., Ltd
2024-04-14 – 2026-12-31 · Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)
What this study did
Phase 1/2 (2)
Multiple Myeloma
Other / comorbidity
NCT06431243 · Chengdu Zenitar Biomedical Technology Co., Ltd
2024-05-08 – 2026-11-01 · Advanced Solid Tumor
What this study did
Phase 1 (2)
Diffuse Large B-Cell Lymphoma
NCT05526313 · Chengdu Zenitar Biomedical Technology Co., Ltd
2020-08-10 – 2024-03-29 · Diffuse Large B Cell Lymphoma,DLBCL
What this study did
Other / comorbidity
NCT07809217 · Chengdu Zenitar Biomedical Technology Co., Ltd
2026-11-09 – 2027-01-31 · MB
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, 4 of them ahead of this one.

This drug's own stage for Diffuse Large B-Cell Lymphoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Purinostat Mesylate: this drugPhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
Brentuximab VedotinApprovedAntibody–drug conjugateAnti-CD30 antibody-drug conjugatenot yet gradedNo reviewed efficacy summary in this indication
EpcoritamabApprovedMultispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
Givinostat
Approved(overall)
Small moleculeHDAC
Reliable signal(overall)
No reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic Antibodynot yet gradedNo reviewed efficacy summary in this indication
Romidepsin
Approved(overall)
Small moleculeHDAC
not yet graded(overall)
No reviewed efficacy summary in this indication
TafasitamabApprovedMonoclonal antibodyCD19Weak signal
NCT02399085: Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants
Vorinostat
Approved(overall)
Small moleculeHDAC
not yet graded(overall)
No reviewed efficacy summary in this indication
AcalabrutinibPhase 3Small moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
IbrutinibPhase 3Small moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
OdronextamabPhase 3Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
SHR-A1912Phase 3Antibody–drug conjugateCD79bnot yet gradedNo reviewed efficacy summary in this indication
Zilovertamab VedotinPhase 2/3Antibody–drug conjugateROR1not yet gradedNo reviewed efficacy summary in this indication
Zugocabtagene Geleucel
Phase 1/2(overall)
Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
REC-2282
Discontinued
Small moleculeHDAC
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Purinostat Mesylate to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1MBRecruiting
Est. primary completion 2026-12-15 · NCT07809217 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2026-12-30 · NCT05563844 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
Phase 3Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2029-06-30 · NCT07011056 · CT.gov ↗
What to watch

See the full readout calendar ↗